Top Quality Edaravone CAS 89-25-8

Factory Supply Best P-Hydroxybenzaldehyde CAS 123-08-0
Supply Best P-Hydroxyacetophenone CAS 99-93-4

Name: Edaravone

Cas: 89-25-8

Purity: 99%min


Directory Guidance on Edaravone

Chemical Structure


Basic Info:

CAS No:89-25-8
Stock AvailabilityIn stock
Brand NameLook chem

Product Introduction:

Edaravone is a nootropic and neuroprotective agent used to aid nervous system recovery after acute cerebral ischemia and subsequent cerebral infarction.

The product was first listed in Japan in April 2001, and is mainly used for the treatment of ischemic stroke in clinical practice.

Edaravone exists in the form of anion and can donate one electron to free radicals to achieve the purpose of scavenging free radicals.

Because its molecular structure contains lipophilic groups, it can easily reach the brain tissue through the blood-brain barrier, and has a protective effect on nerve cell damage caused by cerebral ischemia.

Clinical studies of Edaravone suggest that N-acetylaspartic acid (NAA) is a specific marker of surviving nerve cells, and its content is sharply reduced in the early stage of cerebral infarction.

Edaravone has been shown to attenuate methamphetamine- and 6-OHDA-induced dopaminergic neurotoxicity in the striatum and substantia nigra and did not affect methamphetamine-induced dopamine release or hyperthermia.

It has also been shown to prevent MPTP-mediated dopaminergic neurotoxicity in the substantia nigra, but not in the striatum in particular.

Nature and Specifications:

Product Packaging


Product Usage:

Edaravone is mainly used to synthesize pyrazolone antipyretic analgesics such as dipyrone, antipyrine and aminopyrine.

It is also an intermediate of pyrazolone acid dyes such as acid medium jujube red BN, permanent yellow G and color film dyes, pesticides and other fine chemicals.

Edaravone can be used as a reagent for the determination of cobalt, copper, iron, nickel, silver and vitamin B12.

It can be used as an environmentally friendly reagent and a reagent for ESI/MALDI-MS detection of reducing carbohydrates.

Used in the production of pyrazolone acid dyes such as acid bordeaux BN, acid mordant B, orange GR, weak acid bright yellow G, neutral burgundy D-BN, permanent yellow G, leather spray red GL, orange 2RL, brown 2RL / Active disperse bright yellow 3G, yellow brown M-3GR, etc.

Indications for Edaravone:

Currently, edaravone is mainly used for the treatment of ischemic stroke.

However, its free radical scavenging and antioxidant effects have been confirmed, and various experimental studies have also shown that edaravone has a protective effect on other organ damage.

It is suggested that the role of it is not only limited to the treatment of ischemic stroke, but also plays a role in the treatment of various diseases closely related to oxidative stress.

Japan, as the original research country, is also used in multiple departments in the application of edaravone, such as neurology, brain surgery, cardiology, internal medicine, thoracic surgery, emergency department, surgery, respiratory department, gastroenterology, plastic surgery and pediatrics.

The specific application areas of Edaravone are as follows:

  • Neurology: mainly used in cerebral infarction, viral encephalitis, facial neuritis, epilepsy
  • Neurosurgery: mainly used for cerebral hemorrhage, head injury, spinal cord injury
  • Cardiology: mainly used for myocardial infarction, viral myocarditis
  • Emergency department: mainly used for cerebral infarction, cerebral hemorrhage, craniocerebral injury, carbon monoxide poisoning, paraquat organophosphate poisoning, etc.
  • Orthopedics: mainly used for orthopedic surgery, femoral head necrosis and spinal cord injury, etc.

In addition, there are diabetic peripheral neuropathy in endocrinology;
ENT, ischemic optic nerve injury;
Protection of lungs during thoracotomy in thoracic surgery;
The protection of multiple organs during anesthesia surgery, and its application in oncology and organ transplantation.

Related References:

  1. The good effect of edaravone on patients with acute cerebral large vessel occlusion – PMC | 2015 Mar; 55(3): 241–247.
  2. FDA approves drug to treat ALS – FDA | May 05, 2017.
  3. Wikipedia

Our Promise:

Loading and Transportation

Contact us for the latest quotation and free samples of Edaravone Powder.

Send Inquiry

Hot Products